Published in Vaccine Weekly, March 21st, 2012
"Immunizing with A91 has shown to promote neuroprotection after SCI and its use has proven to be feasible in a clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2012-03-21)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.